Company News

74 press releases in total

2025

Mar 20, 2025

Jacobio Pharma Announces 2024 Annual Results

[More]
Jan 7, 2025

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

[More]

2024

Dec 10, 2024

Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH

[More]
Nov 25, 2024

Jacobio Pharma Completes First Patient Dosage of Pan-KRAS Inhibitor

[More]
Oct 21, 2024

Glecirasib Pancreatic Cancer Indication Received Orphan Drug Designation from EMA

[More]
Oct 9, 2024

Jacobio Presents Pre-clinical Data of SHP2 plus KRAS G12C

[More]
Oct 3, 2024

Jacobio Pharma to Present BET Inhibitor Data at 2024 ASH

[More]
Sep 27, 2024

Jacobio Received RMB 172 million Payment

[More]
Sep 26, 2024

Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from China CDE

[More]
Sep 20, 2024

Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from FDA

[More]
Sep 15, 2024

Jacobio Pharma Presents Efficacy Data of Glecirasib in Combination with JAB-3312 with PD-L1 Expression Levels

[More]
Aug 30, 2024

Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China

[More]
Aug 12, 2024

Jacobio’s SHP2 Inhibitor JAB-3312 Published in Journal of Medicinal Chemistry

[More]
Aug 7, 2024

Jacobio Completes First Patient Dosage in the Phase III Clinical Trial of JAB-3312 in Combination with Glecirasib

[More]
Jul 26, 2024

Jacobio Completes First Patient Dosage of p53 Y220C Activator

[More]
Jul 15, 2024

Jacobio Appoints Dr. Michael Ren as Vice President of Chemistry

[More]
Jun 13, 2024

Jacobio Appoints Dr. Alan Xiao as Vice President of Clinical Pharmacology

[More]
Jun 2, 2024

Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO

[More]
May 21, 2024

Jacobio Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for Glecirasib

[More]
May 10, 2024

Jacobio Announces China CDE Clearance for Phase III Clinical Trial of KRAS G12C Inhibitor Glecirasib in Patients with Colorectal Cancer

[More]

2025

Jacobio Pharma Announces 2024 Annual Results

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

2024

Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH

Jacobio Pharma Completes First Patient Dosage of Pan-KRAS Inhibitor

Glecirasib Pancreatic Cancer Indication Received Orphan Drug Designation from EMA

Jacobio Presents Pre-clinical Data of SHP2 plus KRAS G12C

Jacobio Pharma to Present BET Inhibitor Data at 2024 ASH

Jacobio Received RMB 172 million Payment

Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from China CDE

Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from FDA

Jacobio Pharma Presents Efficacy Data of Glecirasib in Combination with JAB-3312 with PD-L1 Expression Levels

Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China

Jacobio’s SHP2 Inhibitor JAB-3312 Published in Journal of Medicinal Chemistry

Jacobio Completes First Patient Dosage in the Phase III Clinical Trial of JAB-3312 in Combination with Glecirasib

Jacobio Completes First Patient Dosage of p53 Y220C Activator

Jacobio Appoints Dr. Michael Ren as Vice President of Chemistry

Jacobio Appoints Dr. Alan Xiao as Vice President of Clinical Pharmacology

Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO

Jacobio Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for Glecirasib

Jacobio Announces China CDE Clearance for Phase III Clinical Trial of KRAS G12C Inhibitor Glecirasib in Patients with Colorectal Cancer

Pages

About Us

Platform & Pipeline

Partnership

News

Careers

Investor Relations

Search form

Company News

2025

2024

Pages

About Us

Platform & Pipeline

Partnership

News

Careers

Investor Relations